3
7.3 Conclusions .................................................................................................................................................................... 28
8 Airflow / Differential Pressure Characteristics.................................................................................................................... 29
8.1 Summary of Meth ods..................................................................................................................................................... 29
8.2 Results............................................................................................................................................................................ 29
8.3 Conclusions .................................................................................................................................................................... 30
9 Extractabl es Testing ................................................................................................................................................................ 30
9.1 Summary of Meth ods..................................................................................................................................................... 30
9.1.1 Analysis of Material Extracted .......................................................................................................................................31
9.2 Results............................................................................................................................................................................ 32
9.3 Conclusions .................................................................................................................................................................... 33
10 Biological Safety Tests on Components of Emflon HTPFR Filter Cartridges................................................................ 34
10.1 Summary of Meth ods..................................................................................................................................................... 34
10.1.1 Biological Reactivity Tests, In Vivo, for Class VI Plastics-121 °C as per USP <8 8> .................................................34
10.1.2 Biological Reactivity Tests, In Vitro, as per USP <87> (Elution Test).........................................................................35
10.2 Results............................................................................................................................................................................ 35
10.3 Conclusions .................................................................................................................................................................... 35
11 Shelf-Life Studies..................................................................................................................................................................... 35
11.1 Filter Samples for Shelf-Life Studies............................................................................................................................. 35
11.2 Tests for Pall’s Certificate of Test for Pharmaceutical Grade Filters for Shelf-Life Studies ...................................... 36
11.2.1 Fabrication Integrity and Robustness to Autoclaving...................................................................................................36
11.2.2 Summary of Methods to Confirm Meeting “Fabrication Integrity” Acceptance Criteria After Five (5) Years Real
Time Storage..................................................................................................................................................................36
11.2.3 Results for Fabrication Integrity ....................................................................................................................................36
11.2.4 Results for Robustness to Autoclaving .........................................................................................................................36
11.2.5 Bacterial Retention.........................................................................................................................................................37
11.2.6 Summary of Methods to Confirm Meeting “Bacterial Reten tion” Acceptance Criteria After Five (5) Years Real
Time Storage..................................................................................................................................................................37
11.2.7 Results for Bacteria Retention.......................................................................................................................................37
11.2.8 Effluent Quality ...............................................................................................................................................................37
11.2.9 Summary of Methods to Confirm Meeting “Effluent Quality” Acceptance Criteria After Five (5) Years Real Time
Storage ...........................................................................................................................................................................38
11.2.10 Results for Effluent Quality....................................................................................................................................38
11.3 Resistance to Steam Expo sure for Shelf-Life Studies ................................................................................................. 38
11.3.1 Summary of Methods.....................................................................................................................................................38
11.3.2 Results............................................................................................................................................................................39
11.4 Airflow/Differential Pressure Characteristics for Shelf-Life Studies ............................................................................ 39
11.4.1 Summary of Methods.....................................................................................................................................................39
11.4.2 Results............................................................................................................................................................................39
11.5 Conclusion...................................................................................................................................................................... 40
12 Transmissible Spongiform Encephalopathy (TSE) / Bovine Spongiform Encephalopathy (BSE) Statement .......... 41
13 Sample Pharmaceutical Certificate of Test.......................................................................................................................... 41
13.1.1 Fabrication Integrity .......................................................................................................................................................41